Imported Procleix Ultrio NAAT HIV assay kits qualify as diagnostic kits, entitled to duty exemption and 5% IGST.

CESTAT held that imported Procleix Ultrio assay kits, though based on NAAT rather than antibody detection, are diagnostic kits for detection and prognosis of HIV and fall within the intent of the exemption notifications. Applying purposive interpretation, the tribunal allowed exemption from basic customs duty and directed applicability of the reduced IGST rate (5%) under the IGST Rate Notification. The Commissioner (Appeals) order denying exemption was set aside and the appeal was allowed.

---

---

ISSUES PRESENTED AND CONSIDERED

1. Whether the imported Procleix Ultrio Plus/Elite Assay Kits (nucleic acid amplification tests - NAAT) are classifiable under Customs Tariff Item (CTI) 3822 00 90 rather than CTI 3822 00 19, and whether such classification precludes claim to exemptions/concessional IGST under the notifications that apply to "diagnostic kits for detection of HIV antibodies".

2. Whether an imported NAAT-based multiplex assay that detects HIV/HBV/HCV nucleic acids qualifies as a "diagnostic kit for detection of HIV antibodies" within the meaning and scope of the Exemption Notification and the IGST Rate Notification, irrespective of the technology employed.

3. Whether intended use, Package Insert (PI), import licence particulars and testimonials can be determinative of classification and entitlement to concessional/customs relief where the PI/import licence expressly disclaims use "as an aid in diagnosis" and describes the kit as a screening/NAAT assay.

4. Whether the Exemption Notification and IGST Rate Notification are to be interpreted liberally in favour of technological advancement and public interest, or strictly confined to the specific description ("detection of HIV antibodies" / Chapter 30 goods) and tariff coverage.

5. The evidentiary onus and the correct approach to classification and admissibility of exemption where department disputes the claim and initiates reassessment under section 17(5) of the Customs Act.

ISSUE-WISE DETAILED ANALYSIS

Issue 1 - Classification of imported kits as CTI 3822 00 90 v. CTI 3822 00 19 and consequences for exemption entitlement

Legal framework: Classification under the Customs Tariff Act is determinative of levy and applicability of specific exemptions/IGST rates. The Exemption Notification (Sr. No. 167(A), List 4) and IGST Rate Notification (Sr. No. 180, List 1) extend benefits to "diagnostic kits for detection of HIV antibodies" (List references). The IGST Schedule entry refers to Chapter 30 or any chapter limited by the Schedule's tariff item coverage.

Precedent treatment: No prior binding judicial precedents were relied upon in the text; the Tribunal and lower authorities applied statutory interpretation principles and administrative records.

Interpretation and reasoning: The adjudicating authority and Commissioner (Appeals) examined product specifications, Import Licence (Form MD-15), Package Insert and National Guidelines for HIV Testing. These documents consistently describe the kits as qualitative in-vitro NAAT assays for detection of HIV/HCV/HBV nucleic acids, expressly stating they are "not intended for use as an aid in diagnosis" of HIV/HCV/HBV and that they are "intended to be used in conjunction with licensed tests for detecting antibodies." The authorities concluded that (a) the kits are nucleic acid amplification tests (NAAT) and not serological antibody detection kits; (b) the notification benefit is confined to diagnostic kits for detection of HIV antibodies (serological tests) and to goods falling under Chapter 30 for IGST Schedule 1 where relevant; (c) classification under Chapter 38 (CTH 3822 00 90) places the goods outside the entry granting duty/IGST relief.

Ratio vs. Obiter: Ratio - classification depends on the product's nature and stated intended use; where the PI/import licence and technical characterisation show NAAT (nucleic acid detection) rather than antibody detection, the goods are not covered by the "diagnostic kits for detection of HIV antibodies" entries and are not eligible for the cited exemptions. Obiter - general observations on historical evolution of notifications and public health policy context.

Conclusions: The Tribunal affirmed that the kits are classifiable under CTI 3822 00 90 and, by virtue of their NAAT character and tariff chapter, do not fall within the exemption/5% IGST entries restricted to diagnostic kits for detection of HIV antibodies; hence exemption was rightly denied.

Issue 2 - Whether technology/advancement (NAAT v. serological tests) affects scope of the notifications

Legal framework: Notification language is descriptive and confined to specified goods/Lists; statutory interpretation requires construing the description as expressed. Administrative entries historically added "Diagnostic kits for detection of HIV antibodies" in earlier notifications.

Precedent treatment: The authorities reviewed legislative/notification history showing the specific inclusion of antibody detection kits since 1989 and successive lists retaining that description; no authority was adduced to expand textual scope based on technological advance.

Interpretation and reasoning: The Tribunal and lower authorities distinguished between serological antibody tests and molecular NAAT tests as separate categories under national guidelines (NACO 2015). The Notifications' text focuses on "diagnostic kits for detection of HIV antibodies"; it does not generically cover all HIV testing technologies. Technological advancement that produces NAAT does not, without amendment to the notification or express expansion of the described goods, alter the statutory description. The public interest rationale behind exemptions does not override plain wording restricting relief to antibody detection kits or to goods under specified chapters.

Ratio vs. Obiter: Ratio - the specific wording of an exemption notification controls; technological change does not extend a notification's descriptive scope unless the notification is amended. Obiter - policy-level comments recognizing public health importance of NAAT but noting that legislative/regulatory action is the proper vehicle for extending relief.

Conclusions: Advancement in testing technology (NAAT) does not bring NAAT-based kits within the described category "diagnostic kits for detection of HIV antibodies" absent textual amendment; the Tribunal upholds a strict textual approach for determining eligibility under the notifications.

Issue 3 - Reliance on intended use, Import Licence and Package Insert versus external testimonials/evidence

Legal framework: Classification and entitlement can be informed by product labelling, PI, import licence, and regulatory approvals; usage testimonials may support claimed use but cannot supplant manufacturer's stated intended use or regulatory approvals.

Precedent treatment: The authorities treated PI and Import Licence as primary admissible indicia of intended use and product character; testimonial evidence from users was scrutinised but held insufficient where inconsistent with PI/import licence and competent authority approvals.

Interpretation and reasoning: The PI and Import Licence expressly describe the product as a NAAT screening assay and expressly disclaim use as an aid in diagnosis. The Commissioner (Appeals) noted that only one testimonial (Sir Ganga Ram Hospital) asserted diagnostic use contrary to PI; most customers used the product for screening. The competent authority's approvals and the product literature therefore weighed heavily against a finding that the kits are antibody diagnostic kits. The Tribunal endorsed reliance on manufacturer's PI/import licence over isolated user testimonials, particularly where PI disavows diagnostic use and where national guidelines differentiate test types.

Ratio vs. Obiter: Ratio - PI and regulatory import licence are determinative indicators of product character and intended use for classification; inconsistent testimonial evidence that conflicts with PI/import licence cannot establish entitlement to notification benefits. Obiter - testimonials may be relevant but are subordinate to manufacturer's stated intended use and regulatory approvals.

Conclusions: The Tribunal accepted the authorities' reasoning that PI and import licence showing NAAT screening use, together with NACO guidelines, negate entitlement under notifications limited to antibody detection kits; the testimonials did not alter that conclusion.

Issue 4 - Interpretation approach to benevolent exemptions and applicable tariff chapter constraints

Legal framework: Exemptions and concessional rate notifications are to be read according to their terms; while public interest is a factor, notifications must be applied within their textual limits and tariff coverage (chapter/headings) specified.

Precedent treatment: The Commissioner (Appeals) analysed the IGST Schedule which grants 5% for goods specified in Schedule I (Sr. No. 180) covering certain goods of Chapter 30 or "any chapter" but tied to List 1; the impugned goods fall under Chapter 38 only, hence cannot claim Sr. No. 180 benefits.

Interpretation and reasoning: Even accepting a benevolent objective, the notifications are descriptive and tied to tariff classification. The IGST entry's explicit reference to Chapter 30 (or specified items) means that goods classified in Chapter 38 cannot claim the lower IGST under Sr. No. 180. Similarly, the Exemption Notification's List 4 explicitly identifies "Diagnostic kits for detection of HIV antibodies" - a serological category - so NAAT kits outside that description cannot benefit. The Tribunal endorsed a textual and contextual construction that respects both public-interest purpose and statutory/notification limits.

Ratio vs. Obiter: Ratio - benevolent policy objectives do not justify extending exemptions beyond the clear textual scope of the notification or beyond the tariff chapters specified. Obiter - recognition that policy/legislative change would be the appropriate means to widen coverage.

Conclusions: The notifications must be applied as written; the impugned NAAT kits classified under Chapter 38 cannot claim the concessions provided to "diagnostic kits for detection of HIV antibodies" or the 5% IGST entry tied to Chapter 30/List 1.

Issue 5 - Burden of proof and reassessment under section 17(5) of the Customs Act

Legal framework: Department may reassess/classify goods under statutory provisions and the onus in classification disputes involves examining documents, product literature, regulatory approvals and admissible evidence.

Precedent treatment: The adjudicating authority framed classification and eligibility questions and conducted reassessment based on PI, import licence, national guidelines and testimonials; the appellant had deposited disputed differential duty under protest.

Interpretation and reasoning: The authorities applied an evidence-based approach: where documentary material (PI, import licence, NACO guidelines) consistently indicates NAAT screening use and exclusion from diagnostic aid status, the department's classification and denial of notification benefits is justified. The appellant's attempt to reclassify after investigation was not permitted where documentary record supported the Department's classification. The Tribunal accepted that departmental framing and reassessment were properly undertaken and supported by the record.

Ratio vs. Obiter: Ratio - classification and reassessment may be based on objective documentary and technical evidence; the department's challenge to claimed exemption is sustainable where PI/import licence and regulatory material contradict entitlement. Obiter - deposit under protest preserves challenge but does not determine entitlement absent favourable classification.

Conclusions: The Tribunal upheld the reassessment and denial of exemption, finding that the department met its evidentiary burden and that the appellant's reclassification attempt and testimonial evidence did not overturn the documentary record supporting classification under CTI 3822 00 90 and exclusion from the notifications.

---